Plaquenil

Overview

hydroxychloroquine

antimalarial; antirheumatic

• CYP2D6 inhibitor, weak
• intracellular phosphorylation inhibitor
• P-gp inhibitor, weak
• cardiotoxic effects
• hypoglycemic effects
• lowers seizure threshold
• myelosuppressive effects
• peripheral neuropathy
• prolongs QT interval (known)

• monitor ECG in combo with other drugs that prolong QT interval after hydroxychloroquine D/C due to long half-life (32-50 days); combo may incr. risk of QT prolongation, cardiac arrhythmias

Contraindicated

• cisapride
Plaquenil (hydroxychloroquine sulfate)

+

cisapride

1 interaction

Contraindicated

hydroxychloroquine + cisapride

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Plaquenil (hydroxychloroquine sulfate)

+

domperidone

1 interaction

Contraindicated

hydroxychloroquine + domperidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Plaquenil (hydroxychloroquine sulfate)

+

dronedarone

1 interaction

Contraindicated

hydroxychloroquine + dronedarone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• eliglustat
Plaquenil (hydroxychloroquine sulfate)

+

eliglustat

1 interaction

Contraindicated

hydroxychloroquine + eliglustat

CYP2D6 EM: if Child-Pugh Class A, use alternative or monitor ECG, decr. eliglustat dose to 84 mg qd; otherwise, use alternative or monitor ECG; CYP2D6 IM: contraindicated if also combined w/ strong CYP3A4 inhibitor; avoid combo if also combined w/ moderate CYP3A4 inhibitor; otherwise, use alternative or monitor ECG; CYP2D6 PM: contraindicated if also combined w/ strong CYP3A4 inhibitor; avoid combo if also combined w/ weak or moderate CYP3A4 inhibitor; otherwise, use alternative or monitor ECG: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• levoketoconazole
Plaquenil (hydroxychloroquine sulfate)

+

levoketoconazole

1 interaction

Contraindicated

hydroxychloroquine + levoketoconazole

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pimozide
Plaquenil (hydroxychloroquine sulfate)

+

pimozide

1 interaction

Contraindicated

hydroxychloroquine + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• thioridazine
Plaquenil (hydroxychloroquine sulfate)

+

thioridazine

1 interaction

Contraindicated

hydroxychloroquine + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

Avoid/Use Alternative

• adagrasib
Plaquenil (hydroxychloroquine sulfate)

+

adagrasib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol
Plaquenil (hydroxychloroquine sulfate)

+

albuterol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + albuterol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

albuterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + albuterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aldesleukin
Plaquenil (hydroxychloroquine sulfate)

+

aldesleukin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + aldesleukin

avoid combo: combo may incr. risk of myelosuppression, cardiotoxicity, seizures (additive effects)

• alfuzosin
Plaquenil (hydroxychloroquine sulfate)

+

alfuzosin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + alfuzosin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amifampridine
Plaquenil (hydroxychloroquine sulfate)

+

amifampridine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amiodarone
Plaquenil (hydroxychloroquine sulfate)

+

amiodarone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + amiodarone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, peripheral neuropathy (additive effects)

• amisulpride
Plaquenil (hydroxychloroquine sulfate)

+

amisulpride

1 interaction

Avoid/Use Alternative

hydroxychloroquine + amisulpride

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Plaquenil (hydroxychloroquine sulfate)

+

amitriptyline

1 interaction

Avoid/Use Alternative

hydroxychloroquine + amitriptyline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• anagrelide
Plaquenil (hydroxychloroquine sulfate)

+

anagrelide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + anagrelide

use alternative or monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• apalutamide
Plaquenil (hydroxychloroquine sulfate)

+

apalutamide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + apalutamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• apomorphine
Plaquenil (hydroxychloroquine sulfate)

+

apomorphine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + apomorphine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arformoterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

arformoterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + arformoterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Plaquenil (hydroxychloroquine sulfate)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + arsenic trioxide

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• artemether/lumefantrine
Plaquenil (hydroxychloroquine sulfate)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asciminib
Plaquenil (hydroxychloroquine sulfate)

+

asciminib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + asciminib

use alternative or monitor CBC, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression (additive effects)

• asenapine
Plaquenil (hydroxychloroquine sulfate)

+

asenapine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• azithromycin
Plaquenil (hydroxychloroquine sulfate)

+

azithromycin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + azithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Plaquenil (hydroxychloroquine sulfate)

+

bedaquiline

1 interaction

Avoid/Use Alternative

hydroxychloroquine + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Plaquenil (hydroxychloroquine sulfate)

+

berotralstat

1 interaction

Avoid/Use Alternative

hydroxychloroquine + berotralstat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• buprenorphine
Plaquenil (hydroxychloroquine sulfate)

+

buprenorphine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + buprenorphine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• cabozantinib
Plaquenil (hydroxychloroquine sulfate)

+

cabozantinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + cabozantinib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ceritinib
Plaquenil (hydroxychloroquine sulfate)

+

ceritinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ceritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chloramphenicol
Plaquenil (hydroxychloroquine sulfate)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + chloramphenicol

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• chloroquine
Plaquenil (hydroxychloroquine sulfate)

+

chloroquine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + chloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• chlorpromazine
Plaquenil (hydroxychloroquine sulfate)

+

chlorpromazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + chlorpromazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• cimetidine
Plaquenil (hydroxychloroquine sulfate)

+

cimetidine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + cimetidine

avoid combo: combo may incr. hydroxychloroquine levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism possibly inhibited)

• ciprofloxacin
Plaquenil (hydroxychloroquine sulfate)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ciprofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• citalopram
Plaquenil (hydroxychloroquine sulfate)

+

citalopram

1 interaction

Avoid/Use Alternative

hydroxychloroquine + citalopram

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• cladribine oral
Plaquenil (hydroxychloroquine sulfate)

+

cladribine oral

1 interaction

Avoid/Use Alternative

hydroxychloroquine + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Plaquenil (hydroxychloroquine sulfate)

+

clarithromycin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + clarithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clofazimine
Plaquenil (hydroxychloroquine sulfate)

+

clofazimine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + clofazimine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clomipramine
Plaquenil (hydroxychloroquine sulfate)

+

clomipramine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + clomipramine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• clozapine
Plaquenil (hydroxychloroquine sulfate)

+

clozapine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + clozapine

use alternative or monitor CBC, electrolytes, cardiac fxn, incl. ECG, HR, BP; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, hypotension, bradycardia, myelosuppression, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• codeine
Plaquenil (hydroxychloroquine sulfate)

+

codeine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + codeine

use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite morphine levels, efficacy; may incr. risk of seizures (hepatic metabolism inhibited, decr. conversion to morphine; additive effects)

• crizotinib
Plaquenil (hydroxychloroquine sulfate)

+

crizotinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + crizotinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• dasatinib
Plaquenil (hydroxychloroquine sulfate)

+

dasatinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dasatinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• deferiprone
Plaquenil (hydroxychloroquine sulfate)

+

deferiprone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Plaquenil (hydroxychloroquine sulfate)

+

degarelix

1 interaction

Avoid/Use Alternative

hydroxychloroquine + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Plaquenil (hydroxychloroquine sulfate)

+

desflurane

1 interaction

Avoid/Use Alternative

hydroxychloroquine + desflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Plaquenil (hydroxychloroquine sulfate)

+

desipramine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + desipramine

use alternative or monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• deutetrabenazine
Plaquenil (hydroxychloroquine sulfate)

+

deutetrabenazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + deutetrabenazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Plaquenil (hydroxychloroquine sulfate)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Plaquenil (hydroxychloroquine sulfate)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dexmedetomidine injection

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dihydrocodeine
Plaquenil (hydroxychloroquine sulfate)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dihydrocodeine

use alternative or monitor respiratory rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy; may incr. risk of seizures (hepatic metabolism inhibited, decr. conversion to dihydromorphine; additive effects)

• disopyramide
Plaquenil (hydroxychloroquine sulfate)

+

disopyramide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + disopyramide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Plaquenil (hydroxychloroquine sulfate)

+

dofetilide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dofetilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Plaquenil (hydroxychloroquine sulfate)

+

donepezil

1 interaction

Avoid/Use Alternative

hydroxychloroquine + donepezil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• dordaviprone
Plaquenil (hydroxychloroquine sulfate)

+

dordaviprone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + dordaviprone

use alternative or monitor ECG, electrolytes; separate admin.: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Plaquenil (hydroxychloroquine sulfate)

+

droperidol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + droperidol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Plaquenil (hydroxychloroquine sulfate)

+

efavirenz

1 interaction

Avoid/Use Alternative

hydroxychloroquine + efavirenz

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• encorafenib
Plaquenil (hydroxychloroquine sulfate)

+

encorafenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + encorafenib

use alternative or monitor ECG, electrolytes, cardiac fxn (incl. LVEF) if encorafenib used in combo w/ binimetinib: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• entrectinib
Plaquenil (hydroxychloroquine sulfate)

+

entrectinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + entrectinib

use alternative or monitor CBC, cardiac fxn, incl. ECG, LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression (additive effects)

• ephedra
Plaquenil (hydroxychloroquine sulfate)

+

ephedra

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• epirubicin
Plaquenil (hydroxychloroquine sulfate)

+

epirubicin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + epirubicin

use alternative or monitor CBC, cardiac fxn, incl. ECG, LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression (additive effects)

• eribulin
Plaquenil (hydroxychloroquine sulfate)

+

eribulin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + eribulin

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, peripheral neuropathy (additive effects)

• erythromycin
Plaquenil (hydroxychloroquine sulfate)

+

erythromycin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + erythromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• escitalopram
Plaquenil (hydroxychloroquine sulfate)

+

escitalopram

1 interaction

Avoid/Use Alternative

hydroxychloroquine + escitalopram

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• etrasimod
Plaquenil (hydroxychloroquine sulfate)

+

etrasimod

1 interaction

Avoid/Use Alternative

hydroxychloroquine + etrasimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• fexinidazole
Plaquenil (hydroxychloroquine sulfate)

+

fexinidazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after hydroxychloroquine D/C; use alternative or monitor CBC, ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• fingolimod
Plaquenil (hydroxychloroquine sulfate)

+

fingolimod

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fingolimod

use alternative or monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Plaquenil (hydroxychloroquine sulfate)

+

flecainide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + flecainide

use alternative or monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• fluconazole
Plaquenil (hydroxychloroquine sulfate)

+

fluconazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fluconazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Plaquenil (hydroxychloroquine sulfate)

+

fluorouracil

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fluorouracil

use alternative or monitor CBC, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression (additive effects)

• fluoxetine
Plaquenil (hydroxychloroquine sulfate)

+

fluoxetine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fluoxetine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• formoterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

formoterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + formoterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• foscarnet
Plaquenil (hydroxychloroquine sulfate)

+

foscarnet

1 interaction

Avoid/Use Alternative

hydroxychloroquine + foscarnet

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, seizures (additive effects)

• fosfomycin injection
Plaquenil (hydroxychloroquine sulfate)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fosfomycin injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• fostemsavir
Plaquenil (hydroxychloroquine sulfate)

+

fostemsavir

1 interaction

Avoid/Use Alternative

hydroxychloroquine + fostemsavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ganciclovir
Plaquenil (hydroxychloroquine sulfate)

+

ganciclovir

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• gemtuzumab ozogamicin
Plaquenil (hydroxychloroquine sulfate)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + gemtuzumab ozogamicin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• gepirone
Plaquenil (hydroxychloroquine sulfate)

+

gepirone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + gepirone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepotidacin
Plaquenil (hydroxychloroquine sulfate)

+

gepotidacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Plaquenil (hydroxychloroquine sulfate)

+

gilteritinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ginkgo
Plaquenil (hydroxychloroquine sulfate)

+

ginkgo

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ginkgo

avoid consumption of ginkgo seeds; otherwise, caution advised: combo may incr. risk of seizures (additive effects)

• givinostat
Plaquenil (hydroxychloroquine sulfate)

+

givinostat

1 interaction

Avoid/Use Alternative

hydroxychloroquine + givinostat

use alternative or monitor CBC, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• glasdegib
Plaquenil (hydroxychloroquine sulfate)

+

glasdegib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + glasdegib

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• goserelin
Plaquenil (hydroxychloroquine sulfate)

+

goserelin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• granisetron
Plaquenil (hydroxychloroquine sulfate)

+

granisetron

1 interaction

Avoid/Use Alternative

hydroxychloroquine + granisetron

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• grapefruit
Plaquenil (hydroxychloroquine sulfate)

+

grapefruit

1 interaction

Avoid/Use Alternative

hydroxychloroquine + grapefruit

use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• haloperidol
Plaquenil (hydroxychloroquine sulfate)

+

haloperidol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• histrelin
Plaquenil (hydroxychloroquine sulfate)

+

histrelin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Plaquenil (hydroxychloroquine sulfate)

+

hydrocodone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + hydrocodone

use alternative or monitor ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• hydroxyzine
Plaquenil (hydroxychloroquine sulfate)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + hydroxyzine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Plaquenil (hydroxychloroquine sulfate)

+

ibutilide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ibutilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idarubicin
Plaquenil (hydroxychloroquine sulfate)

+

idarubicin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + idarubicin

use alternative at least 5 half-lives after hydroxychloroquine D/C; otherwise, monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• iloperidone
Plaquenil (hydroxychloroquine sulfate)

+

iloperidone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• inotuzumab ozogamicin
Plaquenil (hydroxychloroquine sulfate)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• iohexol
Plaquenil (hydroxychloroquine sulfate)

+

iohexol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• isoflurane
Plaquenil (hydroxychloroquine sulfate)

+

isoflurane

1 interaction

Avoid/Use Alternative

hydroxychloroquine + isoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ivabradine
Plaquenil (hydroxychloroquine sulfate)

+

ivabradine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ivabradine

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ivosidenib
Plaquenil (hydroxychloroquine sulfate)

+

ivosidenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ivosidenib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• lapatinib
Plaquenil (hydroxychloroquine sulfate)

+

lapatinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lapatinib

use alternative or monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• lefamulin
Plaquenil (hydroxychloroquine sulfate)

+

lefamulin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lenvatinib
Plaquenil (hydroxychloroquine sulfate)

+

lenvatinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lenvatinib

use alternative or monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• leuprolide
Plaquenil (hydroxychloroquine sulfate)

+

leuprolide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

levalbuterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + levalbuterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levofloxacin
Plaquenil (hydroxychloroquine sulfate)

+

levofloxacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + levofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• lofexidine
Plaquenil (hydroxychloroquine sulfate)

+

lofexidine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lofexidine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Plaquenil (hydroxychloroquine sulfate)

+

lonafarnib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lonafarnib

use alternative or monitor HR, ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• loperamide
Plaquenil (hydroxychloroquine sulfate)

+

loperamide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Plaquenil (hydroxychloroquine sulfate)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lopinavir/ ritonavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lumateperone
Plaquenil (hydroxychloroquine sulfate)

+

lumateperone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lumateperone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• lurasidone
Plaquenil (hydroxychloroquine sulfate)

+

lurasidone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + lurasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• macimorelin
Plaquenil (hydroxychloroquine sulfate)

+

macimorelin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mavorixafor
Plaquenil (hydroxychloroquine sulfate)

+

mavorixafor

1 interaction

Avoid/Use Alternative

hydroxychloroquine + mavorixafor

use alternative or monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• mefloquine
Plaquenil (hydroxychloroquine sulfate)

+

mefloquine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + mefloquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• meperidine
Plaquenil (hydroxychloroquine sulfate)

+

meperidine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + meperidine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• methadone
Plaquenil (hydroxychloroquine sulfate)

+

methadone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + methadone

use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• metronidazole
Plaquenil (hydroxychloroquine sulfate)

+

metronidazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + metronidazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• midostaurin
Plaquenil (hydroxychloroquine sulfate)

+

midostaurin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + midostaurin

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• mifepristone
Plaquenil (hydroxychloroquine sulfate)

+

mifepristone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + mifepristone

use alternative or monitor ECG if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• milsaperidone
Plaquenil (hydroxychloroquine sulfate)

+

milsaperidone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + milsaperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• mirtazapine
Plaquenil (hydroxychloroquine sulfate)

+

mirtazapine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + mirtazapine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• mobocertinib
Plaquenil (hydroxychloroquine sulfate)

+

mobocertinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + mobocertinib

use alternative or monitor electrolytes, cardiac fxn, incl. ECG, LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• moxifloxacin
Plaquenil (hydroxychloroquine sulfate)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + moxifloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• nilotinib
Plaquenil (hydroxychloroquine sulfate)

+

nilotinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + nilotinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• ofloxacin
Plaquenil (hydroxychloroquine sulfate)

+

ofloxacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures, peripheral neuropathy (additive effects)

• oliceridine
Plaquenil (hydroxychloroquine sulfate)

+

oliceridine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + oliceridine

use alternative or monitor respiratory rate, ECG: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• olodaterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

olodaterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + olodaterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ondansetron
Plaquenil (hydroxychloroquine sulfate)

+

ondansetron

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ondansetron

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Plaquenil (hydroxychloroquine sulfate)

+

osilodrostat

1 interaction

Avoid/Use Alternative

hydroxychloroquine + osilodrostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Plaquenil (hydroxychloroquine sulfate)

+

osimertinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + osimertinib

use alternative or monitor electrolytes, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• oxaliplatin
Plaquenil (hydroxychloroquine sulfate)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + oxaliplatin

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, peripheral neuropathy (additive effects)

• ozanimod
Plaquenil (hydroxychloroquine sulfate)

+

ozanimod

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ozanimod

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Plaquenil (hydroxychloroquine sulfate)

+

pacritinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pacritinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• paliperidone
Plaquenil (hydroxychloroquine sulfate)

+

paliperidone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + paliperidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• palonosetron
Plaquenil (hydroxychloroquine sulfate)

+

palonosetron

1 interaction

Avoid/Use Alternative

hydroxychloroquine + palonosetron

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Plaquenil (hydroxychloroquine sulfate)

+

pasireotide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pasireotide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Plaquenil (hydroxychloroquine sulfate)

+

pazopanib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pazopanib

use alternative or monitor cardiac fxn, incl. ECG, LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• penicillamine
Plaquenil (hydroxychloroquine sulfate)

+

penicillamine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + penicillamine

avoid combo: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Plaquenil (hydroxychloroquine sulfate)

+

pentamidine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pentamidine

use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• phenobarbital
Plaquenil (hydroxychloroquine sulfate)

+

phenobarbital

1 interaction

Avoid/Use Alternative

hydroxychloroquine + phenobarbital

avoid combo if neonatal seizure use; otherwise, use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may alter seizure control (additive effects; antagonistic effects, hydroxychloroquine may decr. seizure threshold)

• pimavanserin
Plaquenil (hydroxychloroquine sulfate)

+

pimavanserin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pimavanserin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pitolisant
Plaquenil (hydroxychloroquine sulfate)

+

pitolisant

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pitolisant

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Plaquenil (hydroxychloroquine sulfate)

+

ponesimod

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ponesimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• posaconazole
Plaquenil (hydroxychloroquine sulfate)

+

posaconazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + posaconazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pralsetinib
Plaquenil (hydroxychloroquine sulfate)

+

pralsetinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + pralsetinib

use alternative or monitor ECG; consider monitoring electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• primaquine
Plaquenil (hydroxychloroquine sulfate)

+

primaquine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + primaquine

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• procainamide
Plaquenil (hydroxychloroquine sulfate)

+

procainamide

1 interaction

Avoid/Use Alternative

hydroxychloroquine + procainamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Plaquenil (hydroxychloroquine sulfate)

+

promethazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + promethazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• propafenone
Plaquenil (hydroxychloroquine sulfate)

+

propafenone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + propafenone

if also combined w/ CYP3A4 inhibitor, avoid use; otherwise, use alternative or monitor cardiac fxn, incl. ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

• quetiapine
Plaquenil (hydroxychloroquine sulfate)

+

quetiapine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + quetiapine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• quinidine (antiarrhythmic)
Plaquenil (hydroxychloroquine sulfate)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

hydroxychloroquine + quinidine (antiarrhythmic)

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Plaquenil (hydroxychloroquine sulfate)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

hydroxychloroquine + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Plaquenil (hydroxychloroquine sulfate)

+

quinine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + quinine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• quizartinib
Plaquenil (hydroxychloroquine sulfate)

+

quizartinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + quizartinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• radium Ra 223 dichloride
Plaquenil (hydroxychloroquine sulfate)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

hydroxychloroquine + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ranolazine
Plaquenil (hydroxychloroquine sulfate)

+

ranolazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ranolazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• relugolix
Plaquenil (hydroxychloroquine sulfate)

+

relugolix

1 interaction

Avoid/Use Alternative

hydroxychloroquine + relugolix

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• remdesivir
Plaquenil (hydroxychloroquine sulfate)

+

remdesivir

1 interaction

Avoid/Use Alternative

hydroxychloroquine + remdesivir

avoid combo: combo may decr. remdesivir active metabolite formation, efficacy (intracellular phosphorylation inhibited, antagonistic effects)

• revumenib
Plaquenil (hydroxychloroquine sulfate)

+

revumenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Plaquenil (hydroxychloroquine sulfate)

+

ribociclib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ribociclib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• rifampin
Plaquenil (hydroxychloroquine sulfate)

+

rifampin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + rifampin

avoid combo: combo may decr. hydroxychloroquine levels, efficacy (hepatic metabolism possibly induced)

• rilpivirine
Plaquenil (hydroxychloroquine sulfate)

+

rilpivirine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + rilpivirine

use alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• romidepsin
Plaquenil (hydroxychloroquine sulfate)

+

romidepsin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + romidepsin

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• ropeginterferon alfa-2b
Plaquenil (hydroxychloroquine sulfate)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ropeginterferon alfa-2b

use alternative or monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• rucaparib
Plaquenil (hydroxychloroquine sulfate)

+

rucaparib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + rucaparib

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• sacituzumab govitecan
Plaquenil (hydroxychloroquine sulfate)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sacituzumab govitecan

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• salmeterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

salmeterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + salmeterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sebetralstat
Plaquenil (hydroxychloroquine sulfate)

+

sebetralstat

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sebetralstat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Plaquenil (hydroxychloroquine sulfate)

+

selpercatinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sertraline
Plaquenil (hydroxychloroquine sulfate)

+

sertraline

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sertraline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• sevoflurane
Plaquenil (hydroxychloroquine sulfate)

+

sevoflurane

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sevoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• siponimod
Plaquenil (hydroxychloroquine sulfate)

+

siponimod

1 interaction

Avoid/Use Alternative

hydroxychloroquine + siponimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• solifenacin
Plaquenil (hydroxychloroquine sulfate)

+

solifenacin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + solifenacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sorafenib
Plaquenil (hydroxychloroquine sulfate)

+

sorafenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sorafenib

use alternative or monitor electrolytes, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• sotalol
Plaquenil (hydroxychloroquine sulfate)

+

sotalol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sunitinib
Plaquenil (hydroxychloroquine sulfate)

+

sunitinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + sunitinib

use alternative or monitor ECG, electrolytes, cardiac fxn; consider monitoring LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• tacrolimus
Plaquenil (hydroxychloroquine sulfate)

+

tacrolimus

1 interaction

Avoid/Use Alternative

hydroxychloroquine + tacrolimus

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• taletrectinib
Plaquenil (hydroxychloroquine sulfate)

+

taletrectinib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + taletrectinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tazemetostat
Plaquenil (hydroxychloroquine sulfate)

+

tazemetostat

1 interaction

Avoid/Use Alternative

hydroxychloroquine + tazemetostat

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• telavancin
Plaquenil (hydroxychloroquine sulfate)

+

telavancin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + telavancin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• terbutaline
Plaquenil (hydroxychloroquine sulfate)

+

terbutaline

1 interaction

Avoid/Use Alternative

hydroxychloroquine + terbutaline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• tetrabenazine
Plaquenil (hydroxychloroquine sulfate)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + tetrabenazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tolterodine
Plaquenil (hydroxychloroquine sulfate)

+

tolterodine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + tolterodine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• toremifene
Plaquenil (hydroxychloroquine sulfate)

+

toremifene

1 interaction

Avoid/Use Alternative

hydroxychloroquine + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Plaquenil (hydroxychloroquine sulfate)

+

tramadol

1 interaction

Avoid/Use Alternative

hydroxychloroquine + tramadol

use alternative or monitor respiratory rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite; additive effects)

• trazodone
Plaquenil (hydroxychloroquine sulfate)

+

trazodone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + trazodone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Plaquenil (hydroxychloroquine sulfate)

+

triclabendazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + triclabendazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Plaquenil (hydroxychloroquine sulfate)

+

trifluridine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + trifluridine

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• triptorelin
Plaquenil (hydroxychloroquine sulfate)

+

triptorelin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• valbenazine
Plaquenil (hydroxychloroquine sulfate)

+

valbenazine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + valbenazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valganciclovir
Plaquenil (hydroxychloroquine sulfate)

+

valganciclovir

1 interaction

Avoid/Use Alternative

hydroxychloroquine + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• vandetanib
Plaquenil (hydroxychloroquine sulfate)

+

vandetanib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + vandetanib

use alternative or monitor electrolytes, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• vardenafil
Plaquenil (hydroxychloroquine sulfate)

+

vardenafil

1 interaction

Avoid/Use Alternative

hydroxychloroquine + vardenafil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Plaquenil (hydroxychloroquine sulfate)

+

vemurafenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• venlafaxine
Plaquenil (hydroxychloroquine sulfate)

+

venlafaxine

1 interaction

Avoid/Use Alternative

hydroxychloroquine + venlafaxine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• vilanterol inhaled
Plaquenil (hydroxychloroquine sulfate)

+

vilanterol inhaled

1 interaction

Avoid/Use Alternative

hydroxychloroquine + vilanterol inhaled

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voclosporin
Plaquenil (hydroxychloroquine sulfate)

+

voclosporin

1 interaction

Avoid/Use Alternative

hydroxychloroquine + voclosporin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voriconazole
Plaquenil (hydroxychloroquine sulfate)

+

voriconazole

1 interaction

Avoid/Use Alternative

hydroxychloroquine + voriconazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziftomenib
Plaquenil (hydroxychloroquine sulfate)

+

ziftomenib

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ziftomenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Plaquenil (hydroxychloroquine sulfate)

+

ziprasidone

1 interaction

Avoid/Use Alternative

hydroxychloroquine + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

Monitor/Modify Tx

• abemaciclib
Plaquenil (hydroxychloroquine sulfate)

+

abemaciclib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + abemaciclib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• acalabrutinib
Plaquenil (hydroxychloroquine sulfate)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + acalabrutinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• adalimumab
Plaquenil (hydroxychloroquine sulfate)

+

adalimumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + adalimumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• ado-trastuzumab emtansine
Plaquenil (hydroxychloroquine sulfate)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ado-trastuzumab emtansine

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity, peripheral neuropathy (additive effects)

• afamitresgene autoleucel
Plaquenil (hydroxychloroquine sulfate)

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + afamitresgene autoleucel

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• aficamten
Plaquenil (hydroxychloroquine sulfate)

+

aficamten

1 interaction

Monitor/Modify Tx

hydroxychloroquine + aficamten

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• albendazole
Plaquenil (hydroxychloroquine sulfate)

+

albendazole

1 interaction

Monitor/Modify Tx

hydroxychloroquine + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alemtuzumab
Plaquenil (hydroxychloroquine sulfate)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• allopurinol
Plaquenil (hydroxychloroquine sulfate)

+

allopurinol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alogliptin
Plaquenil (hydroxychloroquine sulfate)

+

alogliptin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + alogliptin

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• anti-thymocyte globulin
Plaquenil (hydroxychloroquine sulfate)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• atidarsagene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• auranofin
Plaquenil (hydroxychloroquine sulfate)

+

auranofin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avelumab
Plaquenil (hydroxychloroquine sulfate)

+

avelumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + avelumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• axicabtagene ciloleucel
Plaquenil (hydroxychloroquine sulfate)

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + axicabtagene ciloleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• axitinib
Plaquenil (hydroxychloroquine sulfate)

+

axitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + axitinib

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• azacitidine
Plaquenil (hydroxychloroquine sulfate)

+

azacitidine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + azacitidine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azathioprine
Plaquenil (hydroxychloroquine sulfate)

+

azathioprine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• balsalazide
Plaquenil (hydroxychloroquine sulfate)

+

balsalazide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Plaquenil (hydroxychloroquine sulfate)

+

baricitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• belantamab mafodotin
Plaquenil (hydroxychloroquine sulfate)

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + belantamab mafodotin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• belinostat
Plaquenil (hydroxychloroquine sulfate)

+

belinostat

1 interaction

Monitor/Modify Tx

hydroxychloroquine + belinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bendamustine
Plaquenil (hydroxychloroquine sulfate)

+

bendamustine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bendamustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Plaquenil (hydroxychloroquine sulfate)

+

benznidazole

1 interaction

Monitor/Modify Tx

hydroxychloroquine + benznidazole

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• betibeglogene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Plaquenil (hydroxychloroquine sulfate)

+

bevacizumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bevacizumab

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• bexagliflozin
Plaquenil (hydroxychloroquine sulfate)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bexagliflozin

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• bexarotene
Plaquenil (hydroxychloroquine sulfate)

+

bexarotene

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bexarotene

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bezlotoxumab
Plaquenil (hydroxychloroquine sulfate)

+

bezlotoxumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bezlotoxumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• binimetinib
Plaquenil (hydroxychloroquine sulfate)

+

binimetinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + binimetinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• blinatumomab
Plaquenil (hydroxychloroquine sulfate)

+

blinatumomab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + blinatumomab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• bortezomib
Plaquenil (hydroxychloroquine sulfate)

+

bortezomib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bortezomib

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity, peripheral neuropathy (additive effects)

• bosutinib
Plaquenil (hydroxychloroquine sulfate)

+

bosutinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bosutinib

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• brentuximab vedotin
Plaquenil (hydroxychloroquine sulfate)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + brentuximab vedotin

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• brexucabtagene autoleucel
Plaquenil (hydroxychloroquine sulfate)

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + brexucabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• bromocriptine
Plaquenil (hydroxychloroquine sulfate)

+

bromocriptine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bromocriptine

monitor glucose in type 2 diabetes mellitus pts: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• bupropion
Plaquenil (hydroxychloroquine sulfate)

+

bupropion

1 interaction

Monitor/Modify Tx

hydroxychloroquine + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• busulfan
Plaquenil (hydroxychloroquine sulfate)

+

busulfan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + busulfan

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• cabazitaxel
Plaquenil (hydroxychloroquine sulfate)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cabazitaxel

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• canagliflozin
Plaquenil (hydroxychloroquine sulfate)

+

canagliflozin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + canagliflozin

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• capecitabine
Plaquenil (hydroxychloroquine sulfate)

+

capecitabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + capecitabine

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• carboplatin
Plaquenil (hydroxychloroquine sulfate)

+

carboplatin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + carboplatin

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• carfilzomib
Plaquenil (hydroxychloroquine sulfate)

+

carfilzomib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + carfilzomib

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• carmustine
Plaquenil (hydroxychloroquine sulfate)

+

carmustine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + carmustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• certolizumab pegol
Plaquenil (hydroxychloroquine sulfate)

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + certolizumab pegol

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• chlorambucil
Plaquenil (hydroxychloroquine sulfate)

+

chlorambucil

1 interaction

Monitor/Modify Tx

hydroxychloroquine + chlorambucil

monitor CBC; consider chlorambucil dose adjustment: combo may incr. risk of myelosuppression, seizures (additive effects)

• cidofovir
Plaquenil (hydroxychloroquine sulfate)

+

cidofovir

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Plaquenil (hydroxychloroquine sulfate)

+

cilostazol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cilostazol

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• ciltacabtagene autoleucel
Plaquenil (hydroxychloroquine sulfate)

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ciltacabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• cisplatin
Plaquenil (hydroxychloroquine sulfate)

+

cisplatin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cisplatin

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• cladribine injection
Plaquenil (hydroxychloroquine sulfate)

+

cladribine injection

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cladribine injection

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clofarabine
Plaquenil (hydroxychloroquine sulfate)

+

clofarabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + clofarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cobimetinib
Plaquenil (hydroxychloroquine sulfate)

+

cobimetinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cobimetinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• colchicine
Plaquenil (hydroxychloroquine sulfate)

+

colchicine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• colesevelam
Plaquenil (hydroxychloroquine sulfate)

+

colesevelam

1 interaction

Monitor/Modify Tx

hydroxychloroquine + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• copanlisib
Plaquenil (hydroxychloroquine sulfate)

+

copanlisib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + copanlisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• copper histidinate
Plaquenil (hydroxychloroquine sulfate)

+

copper histidinate

1 interaction

Monitor/Modify Tx

hydroxychloroquine + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cyclophosphamide
Plaquenil (hydroxychloroquine sulfate)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cyclophosphamide

monitor CBC, cardiotoxicity: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• cyclosporine
Plaquenil (hydroxychloroquine sulfate)

+

cyclosporine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, seizures, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• cytarabine
Plaquenil (hydroxychloroquine sulfate)

+

cytarabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + cytarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dabrafenib
Plaquenil (hydroxychloroquine sulfate)

+

dabrafenib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dabrafenib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• dacarbazine
Plaquenil (hydroxychloroquine sulfate)

+

dacarbazine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dacarbazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dactinomycin
Plaquenil (hydroxychloroquine sulfate)

+

dactinomycin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dactinomycin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dapsone
Plaquenil (hydroxychloroquine sulfate)

+

dapsone

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daratumumab
Plaquenil (hydroxychloroquine sulfate)

+

daratumumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + daratumumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daunorubicin
Plaquenil (hydroxychloroquine sulfate)

+

daunorubicin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + daunorubicin

monitor CBC, bleeding signs/symptoms, cardiac function, including LVEF: combo may incr. risk of myelosuppression, bleeding (including life-threatening), cardiotoxicity (additive effects)

• decitabine
Plaquenil (hydroxychloroquine sulfate)

+

decitabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + decitabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deferasirox
Plaquenil (hydroxychloroquine sulfate)

+

deferasirox

1 interaction

Monitor/Modify Tx

hydroxychloroquine + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deuruxolitinib
Plaquenil (hydroxychloroquine sulfate)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + deuruxolitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dexrazoxane
Plaquenil (hydroxychloroquine sulfate)

+

dexrazoxane

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dexrazoxane

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• digoxin
Plaquenil (hydroxychloroquine sulfate)

+

digoxin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + digoxin

monitor digoxin levels, HR: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• dinutuximab
Plaquenil (hydroxychloroquine sulfate)

+

dinutuximab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dinutuximab

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• docetaxel
Plaquenil (hydroxychloroquine sulfate)

+

docetaxel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + docetaxel

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• dostarlimab
Plaquenil (hydroxychloroquine sulfate)

+

dostarlimab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + dostarlimab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• doxorubicin
Plaquenil (hydroxychloroquine sulfate)

+

doxorubicin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + doxorubicin

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• duvelisib
Plaquenil (hydroxychloroquine sulfate)

+

duvelisib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + duvelisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• eflornithine
Plaquenil (hydroxychloroquine sulfate)

+

eflornithine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + eflornithine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• elivaldogene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, seizures (additive effects)

• elranatamab
Plaquenil (hydroxychloroquine sulfate)

+

elranatamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + elranatamab

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• enfortumab vedotin
Plaquenil (hydroxychloroquine sulfate)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + enfortumab vedotin

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• epcoritamab
Plaquenil (hydroxychloroquine sulfate)

+

epcoritamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + epcoritamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ertugliflozin
Plaquenil (hydroxychloroquine sulfate)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ertugliflozin

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• etanercept
Plaquenil (hydroxychloroquine sulfate)

+

etanercept

1 interaction

Monitor/Modify Tx

hydroxychloroquine + etanercept

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• etoposide
Plaquenil (hydroxychloroquine sulfate)

+

etoposide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + etoposide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• etuvetidigene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• everolimus
Plaquenil (hydroxychloroquine sulfate)

+

everolimus

1 interaction

Monitor/Modify Tx

hydroxychloroquine + everolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• exagamglogene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• exenatide
Plaquenil (hydroxychloroquine sulfate)

+

exenatide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + exenatide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• fam-trastuzumab deruxtecan
Plaquenil (hydroxychloroquine sulfate)

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + fam-trastuzumab deruxtecan

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• fedratinib
Plaquenil (hydroxychloroquine sulfate)

+

fedratinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + fedratinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• floxuridine
Plaquenil (hydroxychloroquine sulfate)

+

floxuridine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + floxuridine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flucytosine
Plaquenil (hydroxychloroquine sulfate)

+

flucytosine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludarabine
Plaquenil (hydroxychloroquine sulfate)

+

fludarabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + fludarabine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluphenazine
Plaquenil (hydroxychloroquine sulfate)

+

fluphenazine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• fostamatinib
Plaquenil (hydroxychloroquine sulfate)

+

fostamatinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gemcitabine
Plaquenil (hydroxychloroquine sulfate)

+

gemcitabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + gemcitabine

monitor CBC; risk may be lower w/ intravesical gemcitabine administration: combo may incr. risk of myelosuppression (additive effects)

• glimepiride
Plaquenil (hydroxychloroquine sulfate)

+

glimepiride

1 interaction

Monitor/Modify Tx

hydroxychloroquine + glimepiride

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• glipizide
Plaquenil (hydroxychloroquine sulfate)

+

glipizide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + glipizide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• glofitamab
Plaquenil (hydroxychloroquine sulfate)

+

glofitamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + glofitamab

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• glyburide
Plaquenil (hydroxychloroquine sulfate)

+

glyburide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + glyburide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• golimumab
Plaquenil (hydroxychloroquine sulfate)

+

golimumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + golimumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• heparin
Plaquenil (hydroxychloroquine sulfate)

+

heparin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + heparin

monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

• hydroxyurea
Plaquenil (hydroxychloroquine sulfate)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

hydroxychloroquine + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibritumomab tiuxetan
Plaquenil (hydroxychloroquine sulfate)

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ibritumomab tiuxetan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibrutinib
Plaquenil (hydroxychloroquine sulfate)

+

ibrutinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ibrutinib

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• idecabtagene vicleucel
Plaquenil (hydroxychloroquine sulfate)

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + idecabtagene vicleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• idelalisib
Plaquenil (hydroxychloroquine sulfate)

+

idelalisib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + idelalisib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ifosfamide
Plaquenil (hydroxychloroquine sulfate)

+

ifosfamide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ifosfamide

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity, seizures (additive effects)

• imatinib
Plaquenil (hydroxychloroquine sulfate)

+

imatinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + imatinib

monitor CBC, cardiac fxn: combo may incr. risk of cardiotoxicity, myelosuppression (additive effects)

• imetelstat
Plaquenil (hydroxychloroquine sulfate)

+

imetelstat

1 interaction

Monitor/Modify Tx

hydroxychloroquine + imetelstat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• infliximab
Plaquenil (hydroxychloroquine sulfate)

+

infliximab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + infliximab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• insulin
Plaquenil (hydroxychloroquine sulfate)

+

insulin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + insulin

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• interferon beta 1a
Plaquenil (hydroxychloroquine sulfate)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

hydroxychloroquine + interferon beta 1a

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity, seizures (additive effects)

• interferon beta 1b
Plaquenil (hydroxychloroquine sulfate)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

hydroxychloroquine + interferon beta 1b

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity, seizures (additive effects)

• interferon gamma 1b
Plaquenil (hydroxychloroquine sulfate)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

hydroxychloroquine + interferon gamma 1b

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• iopamidol
Plaquenil (hydroxychloroquine sulfate)

+

iopamidol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + iopamidol

caution advised if intrathecal iopamidol use; consider holding hydroxychloroquine at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irinotecan
Plaquenil (hydroxychloroquine sulfate)

+

irinotecan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + irinotecan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isatuximab
Plaquenil (hydroxychloroquine sulfate)

+

isatuximab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + isatuximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• itraconazole
Plaquenil (hydroxychloroquine sulfate)

+

itraconazole

1 interaction

Monitor/Modify Tx

hydroxychloroquine + itraconazole

monitor cardiac fxn: combo may incr. risk of cardiotoxicity, peripheral neuropathy (additive effects)

• ixabepilone
Plaquenil (hydroxychloroquine sulfate)

+

ixabepilone

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ixabepilone

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• leflunomide
Plaquenil (hydroxychloroquine sulfate)

+

leflunomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + leflunomide

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• lenalidomide
Plaquenil (hydroxychloroquine sulfate)

+

lenalidomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lenalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lifileucel
Plaquenil (hydroxychloroquine sulfate)

+

lifileucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lifileucel

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• linagliptin
Plaquenil (hydroxychloroquine sulfate)

+

linagliptin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + linagliptin

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• linezolid
Plaquenil (hydroxychloroquine sulfate)

+

linezolid

1 interaction

Monitor/Modify Tx

hydroxychloroquine + linezolid

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• linvoseltamab
Plaquenil (hydroxychloroquine sulfate)

+

linvoseltamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + linvoseltamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• liraglutide
Plaquenil (hydroxychloroquine sulfate)

+

liraglutide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + liraglutide

monitor glucose in type 2 diabetes mellitus pts, consider monitoring glucose in obesity pts: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• lisocabtagene maraleucel
Plaquenil (hydroxychloroquine sulfate)

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lisocabtagene maraleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• lixisenatide
Plaquenil (hydroxychloroquine sulfate)

+

lixisenatide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lixisenatide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• lomustine
Plaquenil (hydroxychloroquine sulfate)

+

lomustine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lomustine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• loncastuximab tesirine
Plaquenil (hydroxychloroquine sulfate)

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + loncastuximab tesirine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lovotibeglogene autotemcel
Plaquenil (hydroxychloroquine sulfate)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lurbinectedin
Plaquenil (hydroxychloroquine sulfate)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lurbinectedin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lutetium Lu 177 dotatate
Plaquenil (hydroxychloroquine sulfate)

+

lutetium Lu 177 dotatate

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lutetium Lu 177 dotatate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lutetium Lu 177 vipivotide tetraxetan
Plaquenil (hydroxychloroquine sulfate)

+

lutetium Lu 177 vipivotide tetraxetan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lutetium Lu 177 vipivotide tetraxetan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Plaquenil (hydroxychloroquine sulfate)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• margetuximab
Plaquenil (hydroxychloroquine sulfate)

+

margetuximab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + margetuximab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• mavacamten
Plaquenil (hydroxychloroquine sulfate)

+

mavacamten

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mavacamten

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• melphalan
Plaquenil (hydroxychloroquine sulfate)

+

melphalan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + melphalan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mercaptopurine
Plaquenil (hydroxychloroquine sulfate)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Plaquenil (hydroxychloroquine sulfate)

+

mesalamine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Plaquenil (hydroxychloroquine sulfate)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methotrexate
Plaquenil (hydroxychloroquine sulfate)

+

methotrexate

1 interaction

Monitor/Modify Tx

hydroxychloroquine + methotrexate

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• mirdametinib
Plaquenil (hydroxychloroquine sulfate)

+

mirdametinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mirdametinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• mitomycin
Plaquenil (hydroxychloroquine sulfate)

+

mitomycin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mitomycin

monitor CBC; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of myelosuppression (additive effects)

• mitotane
Plaquenil (hydroxychloroquine sulfate)

+

mitotane

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mitotane

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mitoxantrone
Plaquenil (hydroxychloroquine sulfate)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• mogamulizumab
Plaquenil (hydroxychloroquine sulfate)

+

mogamulizumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mogamulizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• momelotinib
Plaquenil (hydroxychloroquine sulfate)

+

momelotinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + momelotinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• mosunetuzumab
Plaquenil (hydroxychloroquine sulfate)

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mosunetuzumab

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• mycophenolate mofetil
Plaquenil (hydroxychloroquine sulfate)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mycophenolate mofetil

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mycophenolic acid
Plaquenil (hydroxychloroquine sulfate)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

hydroxychloroquine + mycophenolic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nateglinide
Plaquenil (hydroxychloroquine sulfate)

+

nateglinide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + nateglinide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• nelarabine
Plaquenil (hydroxychloroquine sulfate)

+

nelarabine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + nelarabine

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• niraparib
Plaquenil (hydroxychloroquine sulfate)

+

niraparib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + niraparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nortriptyline
Plaquenil (hydroxychloroquine sulfate)

+

nortriptyline

1 interaction

Monitor/Modify Tx

hydroxychloroquine + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of seizures, other adverse effects (hepatic metabolism inhibited, additive effects)

• obecabtagene autoleucel
Plaquenil (hydroxychloroquine sulfate)

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + obecabtagene autoleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• obinutuzumab
Plaquenil (hydroxychloroquine sulfate)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + obinutuzumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ofatumumab
Plaquenil (hydroxychloroquine sulfate)

+

ofatumumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ofatumumab

monitor CBC; myelosuppression risk may be lower w/ ofatumumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• olaparib
Plaquenil (hydroxychloroquine sulfate)

+

olaparib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + olaparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• olsalazine
Plaquenil (hydroxychloroquine sulfate)

+

olsalazine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• paclitaxel
Plaquenil (hydroxychloroquine sulfate)

+

paclitaxel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + paclitaxel

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• palbociclib
Plaquenil (hydroxychloroquine sulfate)

+

palbociclib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + palbociclib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon alfa 2a
Plaquenil (hydroxychloroquine sulfate)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

hydroxychloroquine + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Plaquenil (hydroxychloroquine sulfate)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

hydroxychloroquine + peginterferon beta 1a

monitor cardiac fxn, CBC: combo may incr. risk of cardiotoxicity, myelosuppression, seizures (additive effects)

• pemetrexed
Plaquenil (hydroxychloroquine sulfate)

+

pemetrexed

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pemetrexed

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentostatin
Plaquenil (hydroxychloroquine sulfate)

+

pentostatin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pentostatin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pertuzumab
Plaquenil (hydroxychloroquine sulfate)

+

pertuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pertuzumab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• pioglitazone
Plaquenil (hydroxychloroquine sulfate)

+

pioglitazone

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pioglitazone

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• pirtobrutinib
Plaquenil (hydroxychloroquine sulfate)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pirtobrutinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• polatuzumab vedotin
Plaquenil (hydroxychloroquine sulfate)

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + polatuzumab vedotin

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• pomalidomide
Plaquenil (hydroxychloroquine sulfate)

+

pomalidomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pomalidomide

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• ponatinib
Plaquenil (hydroxychloroquine sulfate)

+

ponatinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ponatinib

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity, peripheral neuropathy (additive effects)

• pralatrexate
Plaquenil (hydroxychloroquine sulfate)

+

pralatrexate

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pralatrexate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pramlintide
Plaquenil (hydroxychloroquine sulfate)

+

pramlintide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pramlintide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• procarbazine
Plaquenil (hydroxychloroquine sulfate)

+

procarbazine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + procarbazine

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• proguanil
Plaquenil (hydroxychloroquine sulfate)

+

proguanil

1 interaction

Monitor/Modify Tx

hydroxychloroquine + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• propranolol
Plaquenil (hydroxychloroquine sulfate)

+

propranolol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• pyrimethamine
Plaquenil (hydroxychloroquine sulfate)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• repaglinide
Plaquenil (hydroxychloroquine sulfate)

+

repaglinide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + repaglinide

monitor glucose: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• ribavirin
Plaquenil (hydroxychloroquine sulfate)

+

ribavirin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rifabutin
Plaquenil (hydroxychloroquine sulfate)

+

rifabutin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + rifabutin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ripretinib
Plaquenil (hydroxychloroquine sulfate)

+

ripretinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ripretinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• rituximab
Plaquenil (hydroxychloroquine sulfate)

+

rituximab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rosiglitazone
Plaquenil (hydroxychloroquine sulfate)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

hydroxychloroquine + rosiglitazone

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• ruxolitinib
Plaquenil (hydroxychloroquine sulfate)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ruxolitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ruxolitinib topical
Plaquenil (hydroxychloroquine sulfate)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ruxolitinib topical

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sarilumab
Plaquenil (hydroxychloroquine sulfate)

+

sarilumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + sarilumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• satralizumab
Plaquenil (hydroxychloroquine sulfate)

+

satralizumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saxagliptin
Plaquenil (hydroxychloroquine sulfate)

+

saxagliptin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + saxagliptin

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• selinexor
Plaquenil (hydroxychloroquine sulfate)

+

selinexor

1 interaction

Monitor/Modify Tx

hydroxychloroquine + selinexor

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• selumetinib
Plaquenil (hydroxychloroquine sulfate)

+

selumetinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + selumetinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• semaglutide
Plaquenil (hydroxychloroquine sulfate)

+

semaglutide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + semaglutide

monitor glucose in type 2 diabetes mellitus pts; consider monitoring glucose in obesity pts: combo may incr. risk of hypoglycemia, including life-threatening (additive effects)

• sirolimus
Plaquenil (hydroxychloroquine sulfate)

+

sirolimus

1 interaction

Monitor/Modify Tx

hydroxychloroquine + sirolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sirolimus albumin-bound
Plaquenil (hydroxychloroquine sulfate)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

hydroxychloroquine + sirolimus albumin-bound

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sitagliptin
Plaquenil (hydroxychloroquine sulfate)

+

sitagliptin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + sitagliptin

monitor cardiac fxn, glucose: combo may incr. risk of cardiotoxicity, hypoglycemia, including life-threatening (additive effects)

• stiripentol
Plaquenil (hydroxychloroquine sulfate)

+

stiripentol

1 interaction

Monitor/Modify Tx

hydroxychloroquine + stiripentol

monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, hydroxychloroquine may decr. seizure threshold)

• streptozocin
Plaquenil (hydroxychloroquine sulfate)

+

streptozocin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + streptozocin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succimer
Plaquenil (hydroxychloroquine sulfate)

+

succimer

1 interaction

Monitor/Modify Tx

hydroxychloroquine + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Plaquenil (hydroxychloroquine sulfate)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tafasitamab
Plaquenil (hydroxychloroquine sulfate)

+

tafasitamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tafasitamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tagraxofusp
Plaquenil (hydroxychloroquine sulfate)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tagraxofusp

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• talazoparib
Plaquenil (hydroxychloroquine sulfate)

+

talazoparib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + talazoparib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• talquetamab
Plaquenil (hydroxychloroquine sulfate)

+

talquetamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + talquetamab

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• tarlatamab
Plaquenil (hydroxychloroquine sulfate)

+

tarlatamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tarlatamab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teclistamab
Plaquenil (hydroxychloroquine sulfate)

+

teclistamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + teclistamab

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• temozolomide
Plaquenil (hydroxychloroquine sulfate)

+

temozolomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + temozolomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• temsirolimus
Plaquenil (hydroxychloroquine sulfate)

+

temsirolimus

1 interaction

Monitor/Modify Tx

hydroxychloroquine + temsirolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teplizumab
Plaquenil (hydroxychloroquine sulfate)

+

teplizumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teriflunomide
Plaquenil (hydroxychloroquine sulfate)

+

teriflunomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• thalidomide
Plaquenil (hydroxychloroquine sulfate)

+

thalidomide

1 interaction

Monitor/Modify Tx

hydroxychloroquine + thalidomide

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• thioguanine
Plaquenil (hydroxychloroquine sulfate)

+

thioguanine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + thioguanine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• thiotepa
Plaquenil (hydroxychloroquine sulfate)

+

thiotepa

1 interaction

Monitor/Modify Tx

hydroxychloroquine + thiotepa

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, seizures (additive effects)

• tisagenlecleucel
Plaquenil (hydroxychloroquine sulfate)

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tisagenlecleucel

monitor CBC: combo may incr. risk of myelosuppression, seizures, peripheral neuropathy (additive effects)

• tivozanib
Plaquenil (hydroxychloroquine sulfate)

+

tivozanib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tivozanib

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• tocilizumab
Plaquenil (hydroxychloroquine sulfate)

+

tocilizumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tocilizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tofacitinib
Plaquenil (hydroxychloroquine sulfate)

+

tofacitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + tofacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• topotecan
Plaquenil (hydroxychloroquine sulfate)

+

topotecan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + topotecan

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• trabectedin
Plaquenil (hydroxychloroquine sulfate)

+

trabectedin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + trabectedin

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• trametinib
Plaquenil (hydroxychloroquine sulfate)

+

trametinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + trametinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• trastuzumab
Plaquenil (hydroxychloroquine sulfate)

+

trastuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + trastuzumab

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• treosulfan
Plaquenil (hydroxychloroquine sulfate)

+

treosulfan

1 interaction

Monitor/Modify Tx

hydroxychloroquine + treosulfan

monitor CBC: combo may incr. risk of myelosuppression, seizures (additive effects)

• trimethoprim
Plaquenil (hydroxychloroquine sulfate)

+

trimethoprim

1 interaction

Monitor/Modify Tx

hydroxychloroquine + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• upadacitinib
Plaquenil (hydroxychloroquine sulfate)

+

upadacitinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + upadacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valproic acid
Plaquenil (hydroxychloroquine sulfate)

+

valproic acid

1 interaction

Monitor/Modify Tx

hydroxychloroquine + valproic acid

monitor CBC; caution advised if seizure disorder use: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, hydroxychloroquine may decr. seizure threshold)

• vancomycin
Plaquenil (hydroxychloroquine sulfate)

+

vancomycin

1 interaction

Monitor/Modify Tx

hydroxychloroquine + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• venetoclax
Plaquenil (hydroxychloroquine sulfate)

+

venetoclax

1 interaction

Monitor/Modify Tx

hydroxychloroquine + venetoclax

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vinblastine
Plaquenil (hydroxychloroquine sulfate)

+

vinblastine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + vinblastine

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• vincristine
Plaquenil (hydroxychloroquine sulfate)

+

vincristine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + vincristine

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• vinorelbine
Plaquenil (hydroxychloroquine sulfate)

+

vinorelbine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + vinorelbine

monitor CBC: combo may incr. risk of myelosuppression, peripheral neuropathy (additive effects)

• zanidatamab
Plaquenil (hydroxychloroquine sulfate)

+

zanidatamab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + zanidatamab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• zanubrutinib
Plaquenil (hydroxychloroquine sulfate)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + zanubrutinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• zenocutuzumab
Plaquenil (hydroxychloroquine sulfate)

+

zenocutuzumab

1 interaction

Monitor/Modify Tx

hydroxychloroquine + zenocutuzumab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• zidovudine
Plaquenil (hydroxychloroquine sulfate)

+

zidovudine

1 interaction

Monitor/Modify Tx

hydroxychloroquine + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziv-aflibercept
Plaquenil (hydroxychloroquine sulfate)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

hydroxychloroquine + ziv-aflibercept

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• zongertinib
Plaquenil (hydroxychloroquine sulfate)

+

zongertinib

1 interaction

Monitor/Modify Tx

hydroxychloroquine + zongertinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)